344079 Flurbiprofen - CAS 5104-49-4 - Calbiochem

344079
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Empirical FormulaCAS #
      C₁₅H₁₃FO₂ 5104-49-4

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      344079-100MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Alu drum 100 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA mixture of S(+) and R(–) enantiomers. A cell-permeable, non-steroidal anti-inflammatory agent that acts as a potent inhibitor of cyclooxygenase (IC50 = 5 nM for LPS-induced COX in human peripheral blood cells). Strongly inhibits insoluble transthyretin (TTR) amyloid fibril formation. Suppresses iNOS expression in RAW 264.7 macrophages. Reduces microglial activation and β-amyloid deposit in APP+PS1 transgenic mice.
          Catalogue Number344079
          Brand Family Calbiochem®
          Synonyms(±)-2-Fluoro-α-methyl[1,1ʹ-biphenyl]-4-acetic Acid, U-27182
          References
          ReferencesJantzen, P.T., et al. 2002. J. Neurosci. 22, 2246.
          Hinz, R., et al. 2001. Pharmacol. Res. 18, 151.
          Klabunde, T., et al. 2000. Nat. Struct. Biol. 7, 312.
          Range, S.P., et al. 2000. Eur. Respir. J. 15, 751.
          van Haeringen, N.J., et al. 2000. J. Ocul. Pharmacol. Ther. 16, 353.
          Curnock, A.P., et al. 1997. J. Pharmacol. Exp. Ther. 282, 339.
          Reindeau, D., et al. 1997. Can. J. Physiol. Pharmacol. 75, 1088.
          Wechter, W.J., et al. 1997. Cancer Res. 57, 4316.
          Karmali, R.A., and Marsh, J. 1986. Prostaglandins Leukot. Med. 23, 11.
          Karmali, R.A., and Marsh, J. 1985. Prostaglandins Leukot. Med. 20, 283.
          Product Information
          CAS number5104-49-4
          ATP CompetitiveN
          FormWhite solid
          Hill FormulaC₁₅H₁₃FO₂
          Chemical formulaC₁₅H₁₃FO₂
          ReversibleN
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Primary TargetCyclooxygenase
          Primary Target IC<sub>50</sub>5 nM for LPS-induced COX
          Purity≥98% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          RTECSDU8341000
          Safety Information
          R PhraseR: 25

          Toxic if swallowed.
          S PhraseS: 36/37/39-45

          Wear suitable protective clothing, gloves and eye/face protection.
          In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Toxic & Carcinogenic / Teratogenic
          Hazardous Materials Attention: Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.
          Storage +15°C to +30°C
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze at -20°C. Stock solutions are stable for up to 6 months at 4°C. Further dilution of stock solution in aqueous medium should be made just prior to use.
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          344079

          References

          Reference overview
          Jantzen, P.T., et al. 2002. J. Neurosci. 22, 2246.
          Hinz, R., et al. 2001. Pharmacol. Res. 18, 151.
          Klabunde, T., et al. 2000. Nat. Struct. Biol. 7, 312.
          Range, S.P., et al. 2000. Eur. Respir. J. 15, 751.
          van Haeringen, N.J., et al. 2000. J. Ocul. Pharmacol. Ther. 16, 353.
          Curnock, A.P., et al. 1997. J. Pharmacol. Exp. Ther. 282, 339.
          Reindeau, D., et al. 1997. Can. J. Physiol. Pharmacol. 75, 1088.
          Wechter, W.J., et al. 1997. Cancer Res. 57, 4316.
          Karmali, R.A., and Marsh, J. 1986. Prostaglandins Leukot. Med. 23, 11.
          Karmali, R.A., and Marsh, J. 1985. Prostaglandins Leukot. Med. 20, 283.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision17-October-2017 JSW
          Synonyms(±)-2-Fluoro-α-methyl[1,1ʹ-biphenyl]-4-acetic Acid, U-27182
          DescriptionA mixture of S(+) and R(-) enantiomers. A cell-permeable, non-steroidal anti-inflammatory (NSAID) agent that acts as a potent inhibitor of cyclooxygenase (IC50 = 5 nM for LPS-induced COX in human peripheral blood cells). The S(+) enantiomer is reported to be more potent as a COX-2 inhibitor than the R(-) enantiomer. Suppresses iNOS expression in RAW 264.7 macrophages. Reduces Aβ loads and Congo Red staining in APP+PS1 transgenic mice
          FormWhite solid
          CAS number5104-49-4
          RTECSDU8341000
          Chemical formulaC₁₅H₁₃FO₂
          Structure formulaStructure formula
          Purity≥98% by HPLC
          SolubilityDMSO (50 mg/ml)
          Storage +15°C to +30°C
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze at -20°C. Stock solutions are stable for up to 6 months at 4°C. Further dilution of stock solution in aqueous medium should be made just prior to use.
          Toxicity Toxic & Carcinogenic / Teratogenic
          Merck USA index14, 4199
          ReferencesJantzen, P.T., et al. 2002. J. Neurosci. 22, 2246.
          Hinz, R., et al. 2001. Pharmacol. Res. 18, 151.
          Klabunde, T., et al. 2000. Nat. Struct. Biol. 7, 312.
          Range, S.P., et al. 2000. Eur. Respir. J. 15, 751.
          van Haeringen, N.J., et al. 2000. J. Ocul. Pharmacol. Ther. 16, 353.
          Curnock, A.P., et al. 1997. J. Pharmacol. Exp. Ther. 282, 339.
          Reindeau, D., et al. 1997. Can. J. Physiol. Pharmacol. 75, 1088.
          Wechter, W.J., et al. 1997. Cancer Res. 57, 4316.
          Karmali, R.A., and Marsh, J. 1986. Prostaglandins Leukot. Med. 23, 11.
          Karmali, R.A., and Marsh, J. 1985. Prostaglandins Leukot. Med. 20, 283.